免疫检查点抑制剂治疗 RET 融合非小细胞肺癌：希望与挑战。
Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges.
机构信息
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, China.
出版信息
Anticancer Drugs. 2023 Oct 1;34(9):979-984. doi: 10.1097/CAD.0000000000001483. Epub 2022 Dec 19.
Immune ch eckpoint inhibitors (ICIs) represent a milestone in advanced nonsmall cell lung cancer (NSCLC). Nevertheless, NSCLC with known oncogenic drivers has been overlooked in most studies evaluating anti-programmed death-1/programmed death ligand 1. Rearranged during transfection proto-oncogene (RET) gene fusion was identified in 1-2% of NSCLC patients. More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy and good tolerability. In contrast, the activity of ICIs in RET fusion NSCLC has not been well characterized. Here, we analyzed the clinical data of ICIs and discussed the suitable time to introduce ICIs in RET fusion NSCLC. Finally, we put forward future strategies to adequately maximize the efficacy of ICIs treatment in patients with RET fusion NSCLC in the upcoming era of combination immunotherapies.
免疫检查点抑制剂（ICIs）代表了晚期非小细胞肺癌（NSCLC）治疗的一个里程碑。然而，在评估抗程序性死亡受体-1/程序性死亡配体 1 的大多数研究中，大多数已知致癌驱动基因的 NSCLC 被忽视了。在 1-2%的 NSCLC 患者中发现了重排基因融合。最近，两种选择性 RET 抑制剂——塞尔帕替尼和普拉替尼，显示出更高的疗效和良好的耐受性。相比之下，ICI 在 RET 融合 NSCLC 中的活性尚未得到很好的描述。在这里，我们分析了 ICI 的临床数据，并讨论了在 RET 融合 NSCLC 中引入 ICI 的合适时机。最后，我们提出了未来的策略，以在即将到来的免疫联合治疗时代，充分最大限度地提高 RET 融合 NSCLC 患者的 ICI 治疗效果。
Zotero 插件